On September 25, 2026 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, reported that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26–30 in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher’s prognostic value in assessing disease risk and predictive value in identifying which patients may benefit from treatment intensification, including adding androgen-deprivation therapy (ADT) to radiation.

"The breadth of research being presented at ASTRO underscores the growing role of genomic information in helping clinicians navigate complex prostate cancer treatment decisions," said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. "These presentations demonstrate how elucidating the molecular components of tumor biology may help personalize treatment decisions for patients across different stages of disease."

The following Decipher-focused studies will be presented at ASTRO 2026:

Oral Presentations

Title: Evaluation of PAM50 Molecular Subtypes in Post-Prostatectomy Salvage Radiotherapy: An NRG Oncology-RTOG 0534 Analysis
Presenter: Shuang Zhao, M.D., M.S.E.
Abstract: 6
Date/Time: Sunday, September 27, 1:30–1:40 p.m. ET
Location: Grand Ballroom

Title: The Role of Docetaxel In Addition to Salvage Radiation and Androgen Deprivation In Men with High Risk Prostate Cancer Post-Prostatectomy: Results of NRG GU002
Presenter: Mark Hurwitz, M.D., FASTRO
Abstract: 250
Date/Time: Tuesday, September 29, 12:40–12:50 p.m. ET
Location: Room 210

Title: Genomic Stratification of Benefit From Short-Term Androgen Deprivation With Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer: An Ancillary Study of RTOG/NRG 0815
Presenter: Angela Jia, M.D., Ph.D.
Abstract: 312
Date/Time: Tuesday, September 29, 3:55– 4:05 p.m. ET
Location: Room 210

Title: Multi-institutional Transcriptomic Characterization of Radiorecurrent Prostate Cancer and Prognostic Biomarkers After Salvage Re-irradiation in the F-SHARP Clinical Trial
Presenter: Abhishek Solanki, M.D., M.S.
Abstract: 314
Date/Time: Tuesday, September 29, 4:15–4:25 p.m. ET
Location: Room 210

Title: Long-Term Transcriptomic Analysis of NRG/RTOG 9601: A Phase 3 Study of Salvage Radiotherapy for Prostate Cancer with or without Anti-Androgen Therapy
Presenter: Krishnan Patel, M.D.
Abstract: 315
Date/Time: Tuesday, September 29, 4:25–4:35 p.m. ET
Location: Room 210
Quick-Pitch Presentation

Title: Real-World Evidence across Prostate RT Modalities: Utilization Shifts, Toxicity and BCR in Genomic Classifier Scored Patients
Presenter: Thomas Kole, M.D., Ph.D.
Abstract: 1166
Date/Time: Tuesday, September 29, 5:35–5:40 p.m. ET
Location: Room 205
Poster Presentations

Title: Preoperative Biopsy Decipher Prostate Genomic Classifier Predicts Earlier Secondary Radiotherapy After Radical Prostatectomy in National Real-World Data
Presenter: Thomas Kole, M.D., Ph.D.
Abstract: 3297
Date/Time: Sunday, September 27, 2:15–3:30 p.m. ET
Location: Poster Hall, Exhibit Hall A

Title: Association of 22-Gene Genomic Classifier with ADT Use with Secondary Radiotherapy: A National Real-World Analysis
Presenter: Andrew Barsky, M.D.
Abstract: 3226
Date/Time: Tuesday, September 29, 2:15–3:30 p.m. ET
Location: Poster Hall, Exhibit Hall A
Additional information is available through the ASTRO 2026 Annual Meeting program.

(Press release, Veracyte, SEP 25, 2026, View Source [SID1234671099])